AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 103 filers reported holding AKERO THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 4.79 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,365,407 | +23.5% | 26,995 | +14.0% | 0.01% | +37.5% |
| Q2 2023 | $1,105,806 | +58.1% | 23,684 | +29.6% | 0.01% | +60.0% |
| Q1 2023 | $699,354 | -30.2% | 18,279 | 0.0% | 0.01% | -37.5% |
| Q4 2022 | $1,001,689 | +88.8% | 18,279 | +17.3% | 0.01% | +60.0% |
| Q3 2022 | $530,499 | +260.3% | 15,580 | 0.0% | 0.01% | +400.0% |
| Q2 2022 | $147,231 | -33.4% | 15,580 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $221,080 | +6.3% | 15,580 | +58.5% | 0.00% | -50.0% |
| Q4 2021 | $207,905 | -5.4% | 9,830 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $219,701 | -9.9% | 9,830 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $243,882 | +50.4% | 9,830 | +75.9% | 0.00% | 0.0% |
| Q1 2021 | $162,137 | +12.4% | 5,589 | 0.0% | 0.00% | +100.0% |
| Q4 2020 | $144,196 | -16.2% | 5,589 | 0.0% | 0.00% | -50.0% |
| Q3 2020 | $172,085 | +23.6% | 5,589 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $139,278 | – | 5,589 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 5,830,203 | $168,435,000 | 13.00% |
| venBio Partners LLC | 2,444,311 | $63,063,000 | 5.57% |
| Versant Venture Management, LLC | 777,727 | $20,065,000 | 2.08% |
| Vivo Capital, LLC | 633,426 | $16,342,000 | 0.73% |
| Redmile Group, LLC | 2,322,557 | $59,922,000 | 0.73% |
| Boxer Capital, LLC | 831,495 | $21,453,000 | 0.69% |
| Integral Health Asset Management, LLC | 85,000 | $2,193,000 | 0.65% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 35,179 | $908,000 | 0.53% |
| HighVista Strategies LLC | 27,739 | $716,000 | 0.46% |
| Cormorant Asset Management, LP | 742,549 | $19,158,000 | 0.46% |